Research Synthesis: NAD+ Metabolism Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reconcile the '0 cross-study disagreements' claim in the abstract and the '0 disagreement(s)' claim in Tensions and Gaps with the explicit biomarker-vs-function divergence described in the Limitations section. Either the disagreement count should be corrected to reflect this tension, or the limitations section should be rewritten to match.
2. Provide the actual inclusion/exclusion criteria, screening counts, and reasons for the funnel's drop from 175 to 12, either inline or in an inspectable methods supplement, so the scope boundary is auditable from the manuscript itself.
3. Either include Ioannidis 2005 and Cruz-Jentoft 2019 in the source bundle or remove reliance on them as methodological citations.
4. Resolve the Conze 2019 evidence_type coding (review vs. primary RCT) and add Holmes 2026 to a clearly identified outcome class in the table.
5. Separate the Tensions and Gaps section into (a) documented tensions with citations and (b) proposed next-step studies with specificity about population, endpoint, and design.
6. Either include the 804-claim extraction detail or a summary table of claim counts per source per outcome class, so that the '804 high-confidence extracted claims' figure in the abstract is traceable to the bundle.

Major issues

• Abstract claim of '0 cross-study disagreements' is contradicted by the Limitations section, which explicitly identifies a principal cross-source disagreement (positive NAD+ elevation in Martens 2018/Conze 2019/Elhassan 2019 vs. null functional outcomes in Connell 2021 and borderline-null pooled estimate in Chen 2024). This internal contradiction undermines the landscape's stated heterogeneity mapping.
• The Tensions and Gaps section quantifies '0 disagreement(s)' which is inconsistent with the limitations discussion. The map fails to faithfully surface the biomarker-vs-function divergence that is the most important tension in this corpus.
• Search summary lists an enormous retrieval window (12 databases) and reports 175 records funneled to 12, but the search queries are loose keyword queries with no documented screening criteria for population, intervention, comparator, or outcome. The audit trail is deferred to a methods_pack.json that cannot be inspected, so the scope boundary is not auditable from the manuscript itself.
• Several sources cited in prose (Yulug 2023, Christen 2026, Conze 2019, Martens 2018, Elhassan 2019, Connell 2021, Chen 2024) are correctly identified in the bundle, but multiple others cited in limitations (Ioannidis 2005, Cruz-Jentoft 2019) are not in the source bundle. The manuscript leans on these external citations for methodological framing without including them in the admitted corpus.

Minor issues

• Outcome-class table reports 'Strongest signal: no extracted directional signal in 5/5 sources' for Contextual Adjacent Evidence, which makes that row's signal-strength claim vacuous. The table is structurally redundant with the per-class prose immediately following.
• The '0 non-orthogonal tension(s)' phrasing is opaque; readers will not know what a non-orthogonal tension is.
• Conze 2019 is coded as 'review' in the evidence_type field of the bundle and as a primary RCT in the source body excerpt (describes an RCT). This miscoding should be reconciled.
• The Tensions and Gaps section conflates the next-step recommendation (run adequately powered studies) with the Tensions/Gaps framing. The two should be separated.
• The Holmes 2026 menopause pilot is not clearly placed in any outcome class in the table, despite being one of the 12 admitted sources.
• Search summary 'Exclusion reasons' field is empty/contradictory, stating no records were excluded at the gates, but the funnel shows substantial exclusion (175 → 12).

Reviewer note

This is an evidence map of NAD+ metabolism effects across 12 admitted sources with explicit outcome-class slicing, source attribution, and a generally appropriate refusal to collapse into a clinical efficacy claim. The 12 sources are all real, citable, and in the bundle. The map's main defects are internal contradictions (the '0 cross-study disagreements' claim in the abstract and Tensions/Gaps section versus the explicit biomarker-vs-function divergence described in Limitations) and a non-auditable scope (the search funnel is detailed but the screening criteria and the 175→12 attrition are not justified inside the manuscript). The synthesis is competent in tone and direction but the contradictions need to be resolved and the tensions section must surface the real disagreement the authors already identified in their own limitations. Net: credible but needs bounded edits; revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis